Expert opinion
RET inhibitors are an exciting development in the fight against non-small cell lung cancer (NSCLC) and thyroid cancers. Watch our expert interviews:
- Dr Alexander Drilon discusses the impact of RET inhibitors for NSCLC
- Professor Lori Wirth introduces RET inhibitors in the management of thyroid cancers
- Professor Fernando Lopez-Rios explains molecular testing for RET alterations
RET inhibitors in non-small cell lung cancer
Dr Alexander Drilon, the Chief of the Early Drug Development Service and an Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, USA, discusses RET inhibitors as a treatment for non-small cell lung cancer (NSCLC).
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
RET inhibitors in thyroid cancer
Professor Lori Wirth, Associate Professor of Medicine at Harvard Medical School and Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital, Boston, USA, discusses the use of RET inhibitors to treat thyroid cancers.
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
Molecular testing for RET alterations
Join Professor Fernando Lopez-Rios, a professor of Pathology and Molecular Pathology from Spain, to learn why it is important to test for rearranged during transfection (RET) gene alterations in patients with non-small cell lung cancer (NSCLC) and thyroid cancer.
Expert-led assessment of relevant clinical guidance
Free scientific information and eLearning for healthcare professionals only
Including CME accreditation, podcasts, webinars and over 50 Learning Zones
Medthority is ad free, so you can learn without distraction
of interest
are looking at
saved
next event
This content has been developed by IMR International (Australia) for Medthority, to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.